JPMorgan lowered the firm’s price target on DexCom (DXCM) to $75 from $90 and keeps a Neutral rating on the shares. The company reported mixed Q32 results with a 2026 growth outlook below estimates, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: